Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

AUTOR(ES)

Simmons, Graham

FONTE

National Academy of Sciences

RESUMO

Severe acute respiratory syndrome (SARS) is caused by an emergent coronavirus (SARS-CoV), for which there is currently no effective treatment. SARS-CoV mediates receptor binding and entry by its spike (S) glycoprotein, and infection is sensitive to lysosomotropic agents that perturb endosomal pH. We demonstrate here that the lysosomotropic-agent-mediated block to SARS-CoV infection is overcome by protease treatment of target-cell-associated virus. In addition, SARS-CoV infection was blocked by specific inhibitors of the pH-sensitive endosomal protease cathepsin L. A cell-free membrane-fusion system demonstrates that engagement of receptor followed by proteolysis is required for SARS-CoV membrane fusion and indicates that cathepsin L is sufficient to activate membrane fusion by SARS-CoV S. These results suggest that SARS-CoV infection results from a unique, three-step process: receptor binding and induced conformational changes in S glycoprotein followed by cathepsin L proteolysis within endosomes. The requirement for cathepsin L proteolysis identifies a previously uncharacterized class of inhibitor for SARS-CoV infection.

Documentos Relacionados

• Small Molecules Blocking the Entry of Severe Acute Respiratory Syndrome Coronavirus into Host Cells
• CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus
• Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry
• Severe Acute Respiratory Syndrome Coronavirus Phylogeny: toward Consensus
• Mosaic Evolution of the Severe Acute Respiratory Syndrome Coronavirus